Intravitreal Aflibercept Injection for Polypoidal Choroidal Vasculopathy With Hemorrhage or Exudation

Inclusion Criteria: * Age \> 25 years of age. * In the opinion of the principal investigator, the study eye has PCV with active exudation and/or bleeding that may benefit from treatment with study medication. * Diagnosis of PCV via ICG Angiography with evidence of active leakage, active bleeding or recent decreased in vision. * Baseline visual acuity better than or equal to 20/200 using ETDRS * Willing and able to comply with clinic visits and study-related procedures * Provide signed informed consent Exclusion Criteria: * Any history of previous vitrectomy * Previous cataract surgery within the preceding 2 months of Day 0 * Active infections conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye * Presence of any condition that would jeopardize the patient's participation in this study * Participation in an investigational trial within 30 days of randomization that involved treatment with any drug that has not received regulatory approval at the time of study entry * For the Treatment-Naïve cohort: no prior anti-VEGF (Macugen, Avastin, Lucentis, Eylea) in the study eye * For the Previous-Treated cohort: no prior anti-VEGF (Macugen, Avastin, Lucentis) in the study eye within 30 days or enrollment in this study * For the Previous-Treated cohort: no prior Eylea in the study eye * Known allergy to any component of the study drug * Blood pressure \>180/119 (systolic above 180 or diastolic above 110). If blood pressure is brought below 180/110 by anti-hypertensive treatment, the patient can be eligible. * Major surgery within 28 days prior to randomization or major surgery planned within the next 12 months. Major surgery is defined as a surgical procedure that is more extensive than needle biopsy/aspiration placement of a central venous access device, removal/biopsy of a skin lesion, or placement of a peripheral venous catheter * Myocardial infarction, other cardiac event requiring hospitalization, stroke, transient ischemic attack, or treatment for acute congestive heart failure within 6 months prior to randomization * Systemic anti-VEGF or pro-VEGF treatment within 3 months prior to randomization * Pregnant or breast-feeding women * Simultaneous participation in another medical investigational trial * Sexually active men\* or women of childbearing potential\*\* who are unwilling to practice adequate contraception during the study (adequate contraceptive measures include stable use of oral contraceptives or other prescription pharmaceutical contraceptives for 2 or more menstrual cycles prior to screening; intrauterine device \[IUD\]; bilateral tubal ligation; vasectomy; condom plus contraceptive sponge, foam, or jelly, or diaphragm plus contraceptive sponge, foam, or jelly)